Trial site
Pillar Clinical Research - Richardson
Richardson, Texas 75080, United StatesNot linked to an institution yet
- 6running trials
- 1closed trial
The trials here
What the 7 trials at this site are about, from their registry records.
- Phase
- Phase 35 trials
- Phase 22 trials
- Status
- Recruiting6 trials
- Completed1 trial
- Lead sponsor
- Bristol-Myers Squibb4 trials
- Eli Lilly and Company1 trial
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company1 trial
- Rapport Therapeutics Inc.1 trial
Running trials
Recruiting
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
NCT07686263· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Contact: Scott Bartley, Site 0133
Recruiting
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
NCT07286175· Phase 2· Eli Lilly and Company· Source
Contact: Scott Bartley (principal investigator)
Recruiting
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
NCT07140913· Phase 3· Bristol-Myers Squibb· Source
Contact: Scott Bartley, Site 0033
Recruiting
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
NCT06929273· Phase 3· Bristol-Myers Squibb· Source
Contact: Scott Bartley, Site 0034
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
NCT06951711· Phase 3· Bristol-Myers Squibb· Source
Contact: Scott Bartley, Site 0037
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
NCT06951698· Phase 3· Bristol-Myers Squibb· Source
Contact: Scott Bartley, Site 0044
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error